Cynthia A. Maryanoff

At 74 years old, Cynthia A. Maryanoff physical status not available right now. We will update Cynthia A. Maryanoff's height, weight, eye color, hair color, build, and measurements.

She joined Smith, Kline & French Laboratories in 1977 and moved to McNeil Pharmaceutical, a Johnson & Johnson subsidiary in 1981. She served as global head of Chemical and Pharmaceutical Development in preclinical development from 2000-2004, which was responsible for moving new chemical entities from small-scale to large-scale chemical synthesis, for analytical methods, and establishing oral formulations for early human studies. Maryanoff advanced through various Johnson & Johnson pharmaceutical units to the highest scientific position in the company.

In 2004 she moved to Cordis (medical) Corporation, a Johnson & Johnson medical device unit, as a Distinguished Research Fellow in the Cordis facility in Spring House, Pennsylvania. She retired from Johnson & Johnson in 2013. Since then she has been a Professor (with Distinction) of Experimental Therapeutics and Medicinal Chemistry at the Baruch S. Blumberg Institute (Doylestown, PA) and a Professor of Drug Delivery at the Pennsylvania Drug Discovery Institute.

Maryanoff has been active in the fields of organic chemistry and materials science. Her publication record includes more than 100 scientific papers and several books. She is listed as an inventor on 67 U.S. or European patents, issued or pending.

Maryanoff emphasizes that accomplishments in process chemistry depend upon the work of teams of people who are involved in the research. As a scientist and group leader she has been influential in creating drug candidates for a variety of conditions, including antipsychotics, antiepileptics, antiviral agents, and treatments for cardiovascular disease and female reproductive diseases. She has also worked on the transdermal delivery of narcotics, pulmonary surfactants, endocrine function, and Cordis drug-eluting stents. The more than 1,000 drug candidates she has been involved in developing include the anti-epileptic Topamax, and an atypical analgesic, Ultram/Tramadol, for treating pain.

She has been active in the American Chemical Society (ACS) in many positions including national election to the Executive Committee of the Division of Organic Chemistry (DOC) (1988–2018). She was the first woman to be chair of the Division of Organic Chemistry (DOC) (1997). She has served on a variety of other committees including the Advisory Board of Chemical & Engineering News, the International Activities Committee (2014-2022), and the ACS Governing Board of Publishing (2015-2023). As well as the ACS, she has been active on the NSF Postdoctoral Research Fellowship Review Panel, the NIH Division of Grants, and the NCI Committee for Proposals to Synthesize Pharmaceutical Agents.

Source